These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34531523)

  • 1. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
    Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
    Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney.
    Kapur P; Gao M; Zhong H; Chintalapati S; Mitui M; Barnes SD; Zhou Q; Miyata J; Carrillo D; Malladi VS; Rakheja D; Pedrosa I; Xu L; Kinch L; Brugarolas J
    Mod Pathol; 2022 Mar; 35(3):333-343. PubMed ID: 34538873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
    Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
    Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
    Alghamdi M; Chen JF; Jungbluth A; Koutzaki S; Palmer MB; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
    Mod Pathol; 2024 May; 37(5):100467. PubMed ID: 38460672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations.
    Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
    Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
    [No Abstract]   [Full Text] [Related]  

  • 6. Concordance of MTOR Pathway Mutations and the Diagnosis of Renal Low-Grade Oncocytic Tumor (LOT).
    Siegmund SE; Al-Obaidy KI; Tsai HK; Idrees MT; Akgul M; Acosta AM; Hirsch MS
    Int J Surg Pathol; 2024 Apr; 32(2):316-330. PubMed ID: 37357748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological features of low-grade oncocytic renal tumor (CD117-negative, cytokeratin 7-positive): report of seven cases].
    Xie B; Cheng LC; Yin GL; Liu BA; Hu ZL; Tong K
    Zhonghua Bing Li Xue Za Zhi; 2022 Aug; 51(8):719-725. PubMed ID: 35922161
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
    Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
    Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
    Tjota MY; Wanjari P; Segal J; Antic T
    Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
    Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
    Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low grade oncocytic renal tumor (LOT): Clinicopathological characterization of 13 cases.
    Almutairi F; Xu B
    Pathol Res Pract; 2024 Feb; 254():155127. PubMed ID: 38241777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.
    Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.
    Mansoor M; Siadat F; Trpkov K
    Histol Histopathol; 2022 May; 37(5):405-413. PubMed ID: 35156688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
    Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
    Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CK7+/CD117- low grade oncocytic tumor of the kidney: a clinicopathological analysis].
    Bai YF; Chang CD; Wang B; Zhao M; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):976-980. PubMed ID: 36207909
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-Grade Oncocytic Tumor: Report of Two Cases of An Emerging Entity in the Spectrum of Oncocytic Renal Neoplasms.
    Sharma D; Pai T; Prakash G; Desai S; Menon S
    Turk Patoloji Derg; 2022; 38(2):162-166. PubMed ID: 34514579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics.
    Kravtsov O; Gupta S; Cheville JC; Sukov WR; Rowsey R; Herrera-Hernandez LP; Lohse CM; Knudson R; Leibovich BC; Jimenez RE
    Hum Pathol; 2021 Aug; 114():9-18. PubMed ID: 33961838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
    Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
    Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China.
    Guo Q; Liu N; Wang F; Guo Y; Yang B; Cao Z; Wang Y; Wang Y; Zhang W; Huang Q; Zhao W; Liu C; Qu T; Li L; Cao L; Ren D; Meng B; Qi L; Wang C; Cao W
    Virchows Arch; 2021 Mar; 478(3):449-458. PubMed ID: 32918598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.